001     169016
005     20240229133635.0
024 7 _ |a 10.1093/neuonc/noab127
|2 doi
024 7 _ |a pmid:34049392
|2 pmid
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:106684518
|2 altmetric
037 _ _ |a DKFZ-2021-01184
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Simovic, Milena
|0 P:(DE-He78)1fdaffee272e57a73f861a0ea36c4079
|b 0
|e First author
|u dkfz
245 _ _ |a Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
260 _ _ |a Oxford
|c 2021
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1642077832_474
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:B420#LA:B420# / 2021 Dec 1;23(12):2028-2041
520 _ _ |a Medulloblastomas with chromothripsis developing in children with Li-Fraumeni Syndrome (germline TP53 mutations) are highly aggressive brain tumors with dismal prognosis. Conventional photon radiotherapy and DNA-damaging chemotherapy are not successful for these patients and raise the risk of secondary malignancies. We hypothesized that the pronounced homologous recombination deficiency in these tumors might offer vulnerabilities that can be therapeutically utilized in combination with high linear energy transfer carbon ion radiotherapy.We tested high-precision particle therapy with carbon ions and protons as well as topotecan with or without PARP inhibitor in orthotopic primary and matched relapsed patient-derived xenograft models. Tumor and normal tissue underwent longitudinal morphological (MRI), cellular (markers of neurogenesis and DNA damage-repair) and molecular characterization (whole-genome sequencing).In the primary medulloblastoma model, carbon ions led to complete response in 79% of animals irrespective of PARP inhibitor within a follow-up period of 300 days post-irradiation, as detected by MRI and histology. No sign of neurologic symptoms, impairment of neurogenesis or in-field carcinogenesis was detected in repair-deficient host mice. PARP inhibitors further enhanced the effect of proton irradiation. In the post-radiotherapy relapsed tumor model, median survival was significantly increased after carbon ions (96 days) versus control (43 days, p<0.0001). No major change in the clonal composition was detected in the relapsed model.The high efficacy and favorable toxicity profile of carbon ions warrants further investigation in primary medulloblastomas with chromothripsis. Post-radiotherapy relapsed medulloblastomas exhibit relative resistance compared to treatment-naïve tumors, calling for exploration of multimodal strategies.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a PARP inhibitor
|2 Other
650 _ 7 |a carbon ion radiotherapy
|2 Other
650 _ 7 |a chromothripsis
|2 Other
650 _ 7 |a medulloblastoma
|2 Other
650 _ 7 |a synthetic lethality
|2 Other
700 1 _ |a Bolkestein, Michiel
|0 P:(DE-He78)2f672b5ff4fc0d5ba62362e2be763b33
|b 1
700 1 _ |a Moustafa, Mahmoud
|0 P:(DE-He78)00f2c4d2003902d3abd37481c5268850
|b 2
|u dkfz
700 1 _ |a Wong, John K L
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Körber, Verena
|0 P:(DE-He78)467f2d039931bfae1a497c4a6c54804c
|b 4
|u dkfz
700 1 _ |a Benedetto, Sarah
|0 P:(DE-He78)d48b860ab71e11457fb448a110b1f308
|b 5
|u dkfz
700 1 _ |a Khalid, Umar
|0 P:(DE-He78)794761a765ceca759536a1bf39100142
|b 6
|u dkfz
700 1 _ |a Schreiber, Hannah Sophia
|0 P:(DE-He78)a1d9ea75dd03dbe8e7cd31adc141d10d
|b 7
|u dkfz
700 1 _ |a Jugold, Manfred
|0 P:(DE-He78)f12dec7b80065347181cf69f8233b40d
|b 8
|u dkfz
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 9
|u dkfz
700 1 _ |a Hübschmann, Daniel
|0 P:(DE-He78)a5218e4871866cd5ab2312e594ca403d
|b 10
|u dkfz
700 1 _ |a Mack, Norman
|0 P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109
|b 11
|u dkfz
700 1 _ |a Brons, Stephan
|0 0000-0002-4695-0816
|b 12
700 1 _ |a Wei, Pei-Chi
|0 P:(DE-He78)56a961d57d7839fc2d2ebb60c575d9c4
|b 13
|u dkfz
700 1 _ |a Breckwoldt, Michael O
|b 14
700 1 _ |a Heiland, Sabine
|b 15
700 1 _ |a Bendszus, Martin
|b 16
700 1 _ |a Jürgen, Debus
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Höfer, Thomas
|0 P:(DE-He78)9dbe272aaadbdc810ab0bb291eae428e
|b 18
|u dkfz
700 1 _ |a Zapatka, Marc
|0 P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7
|b 19
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 20
|u dkfz
700 1 _ |a Pfister, Stefan M
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 21
|u dkfz
700 1 _ |a Abdollahi, Amir
|0 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
|b 22
|u dkfz
700 1 _ |a Ernst, Aurélie
|0 P:(DE-He78)509fb81813c1911954da583129e8ea57
|b 23
|e Last author
|u dkfz
773 _ _ |a 10.1093/neuonc/noab127
|g p. noab127
|0 PERI:(DE-600)2094060-9
|n 12
|p 2028-2041
|t Neuro-Oncology
|v 23
|y 2021
|x 1523-5866
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169016
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)1fdaffee272e57a73f861a0ea36c4079
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2f672b5ff4fc0d5ba62362e2be763b33
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)00f2c4d2003902d3abd37481c5268850
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)467f2d039931bfae1a497c4a6c54804c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d48b860ab71e11457fb448a110b1f308
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)794761a765ceca759536a1bf39100142
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)a1d9ea75dd03dbe8e7cd31adc141d10d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)f12dec7b80065347181cf69f8233b40d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)a5218e4871866cd5ab2312e594ca403d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)e73a0a4fab40344d89d693cbe1df3109
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)56a961d57d7839fc2d2ebb60c575d9c4
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)9dbe272aaadbdc810ab0bb291eae428e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 19
|6 P:(DE-He78)1beba8f953e7ae7e96e8d3e9a48f10f7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 20
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)509fb81813c1911954da583129e8ea57
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-03
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
920 1 _ |0 I:(DE-He78)B420-20160331
|k B420
|l Genominstabilität in Tumoren
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l B060 Molekulare Genetik
|x 2
920 1 _ |0 I:(DE-He78)B086-20160331
|k B086
|l B086 Modellierung Biol. Systeme
|x 3
920 1 _ |0 I:(DE-He78)W240-20160331
|k W240
|l W240 Kleintierbildgebung
|x 4
920 1 _ |0 I:(DE-He78)B300-20160331
|k B300
|l KKE Neuropathologie
|x 5
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 6
920 1 _ |0 I:(DE-He78)B400-20160331
|k B400
|l Hirngenom-Mosaizismus und Tumorgenese
|x 7
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 8
920 1 _ |0 I:(DE-He78)E210-20160331
|k E210
|l E210 Translationale Radioonkologie
|x 9
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B420-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a I:(DE-He78)B086-20160331
980 _ _ |a I:(DE-He78)W240-20160331
980 _ _ |a I:(DE-He78)B300-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B400-20160331
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)E210-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21